iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) was the recipient of a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 1,800,000 shares, an increase of 9.8% from the November 30th total of 1,640,000 shares. Approximately 6.2% of the shares of the company are sold short. Based on an average trading volume of 306,400 shares, the short-interest ratio is presently 5.9 days.
iTeos Therapeutics Price Performance
Shares of ITOS opened at $19.53 on Tuesday. iTeos Therapeutics has a 1-year low of $16.21 and a 1-year high of $52.43. The stock has a market cap of $694.78 million, a PE ratio of 2.84 and a beta of 1.38. The firm has a fifty day moving average price of $19.85 and a 200 day moving average price of $21.20.
Get
iTeos Therapeutics alerts:
iTeos Therapeutics (NASDAQ:ITOS – Get Rating) last announced its quarterly earnings results on Thursday, November 10th. The company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.07 by ($0.04). iTeos Therapeutics had a net margin of 57.48% and a return on equity of 42.62%. The company had revenue of $19.49 million during the quarter, compared to analysts' expectations of $42.05 million. As a group, equities analysts expect that iTeos Therapeutics will post 2.85 EPS for the current fiscal year.
Institutional Investors Weigh In On iTeos Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Prairiewood Capital LLC purchased a new stake in shares of iTeos Therapeutics in the third quarter valued at about $615,000. Alps Advisors Inc. purchased a new stake in shares of iTeos Therapeutics in the second quarter valued at about $434,000. Rafferty Asset Management LLC raised its holdings in shares of iTeos Therapeutics by 2.1% in the second quarter. Rafferty Asset Management LLC now owns 99,368 shares of the company's stock valued at $2,047,000 after buying an additional 2,067 shares during the last quarter. Principal Financial Group Inc. raised its holdings in shares of iTeos Therapeutics by 22.7% in the second quarter. Principal Financial Group Inc. now owns 167,750 shares of the company's stock valued at $3,455,000 after buying an additional 31,004 shares during the last quarter. Finally, Virtus ETF Advisers LLC raised its holdings in shares of iTeos Therapeutics by 39.1% in the second quarter. Virtus ETF Advisers LLC now owns 5,790 shares of the company's stock valued at $119,000 after buying an additional 1,629 shares during the last quarter.
iTeos Therapeutics Company Profile
(Get Rating)
Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
Featured Articles
- Get a free copy of the StockNews.com research report on iTeos Therapeutics (ITOS)
- These 3 Tech Stocks Are in for a Happier New Year
- Can Duke Energy Stock Continue Powering Higher?
- Tyson Foods: Growth, Momentum, Growth At A Reasonable Price
- Ready for a Recession? Here's One Defensive Stock You Can't Miss
- Should You Store Your Capital in Pure Storage Stock?
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
